EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Lidocaine as an anti‐arrhythmic drug: Are there any indications left?

Sati Güler iD, Hilke Könemann, Julian Wolfes, Fatih Güner, Christian Ellermann, Benjamin Rath, Gerrit Frommeyer iD, Philipp Sebastian Lange, Julia Köbe, Florian Reinke, Lars Eckardt iD

Clinical and Translational Science · 2023-12 · 16 (12) · 2429-2437

DOI: 10.1111/cts.13650 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 02.10.2023. Verfasst von Sati Güler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Lidocaine, Amiodarone. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lidocaine is classified as a class Ib anti‐arrhythmic that blocks voltage‐ and pH‐dependent sodium channels. It exhibits well investigated anti‐arrhythmic effects and has been the anti‐arrhythmic of choice for the treatment of ventricular arrhythmias for several decades. Lidocaine binds primarily to inactivated sodium channels, decreases the action potential duration, and increases the refractory period. It increases the ventricular fibrillatory threshold and can interrupt life‐threatening tachycardias caused by re‐entrant mechanisms, especially in ischemic tissue. Its use was pushed into the background in the era of amiodarone and modern electric device therapy. Recently, lidocaine has come back into focus for the treatment of acute sustained ventricular tachyarrhythmias. In this brief overview, we review the clinical pharmacology including possible side effects, the historical course, possible indications, and current Guideline recommendations for the use of lidocaine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LidocaineAmiodaroneHumansAnti-Arrhythmia AgentsArrhythmias, CardiacSodium Channels

Substanzen

LidocaineAnti-Arrhythmia AgentsAmiodaroneSodium Channels

Autor:innen und Institutionen

  • Department of Cardiology II: Electrophysiology, University Hospital Münster, Münster, Germany.

ORCID-Profile: Sati Güler, Gerrit Frommeyer, Lars Eckardt

Zitieren

APA

Güler, S., Könemann, H., Wolfes, J., Güner, F., Ellermann, C., Rath, B., Frommeyer, G., Lange, P. S., Köbe, J., Reinke, F., & Eckardt, L. (2023). Lidocaine as an anti‐arrhythmic drug: Are there any indications left?. Clinical and Translational Science, 16(12), 2429-2437. https://doi.org/10.1111/cts.13650

Vancouver

Güler S, Könemann H, Wolfes J, Güner F, Ellermann C, Rath B, et al. Lidocaine as an anti‐arrhythmic drug: Are there any indications left?. Clinical and Translational Science. 2023;16(12):2429-2437. doi:10.1111/cts.13650

BibTeX
@article{Gler2023,
  author = {Güler, Sati and Könemann, Hilke and Wolfes, Julian and Güner, Fatih and Ellermann, Christian and Rath, Benjamin and Frommeyer, Gerrit and Lange, Philipp Sebastian and Köbe, Julia and Reinke, Florian and Eckardt, Lars},
  title = {Lidocaine as an anti‐arrhythmic drug: Are there any indications left?},
  journal = {Clinical and Translational Science},
  year = {2023},
  volume = {16},
  number = {12},
  pages = {2429--2437},
  doi = {10.1111/cts.13650}
}
Kostenlos starten →